Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Tag: MONOGRAPH

Iclepertin

Our opinion on this compoundNiche research probe

46/100

Best-in-class GlyT1 probe with real Phase II signal, sunk by decisive Phase III replication failure

Iclepertin (BI 425809) came out of Boehringer Ingelheim’s push to do the GlyT1 inhibition story properly. The mechanism rationale is real: block GlyT1 astrocytic reuptake, saturate the NMDA glycine-B co-agonist site, and you’re effectively turning up the gain on glutamatergic neurotransmission in circuits that NMDA hypofunction models have implicated in schizophrenia’s cognitive deficits for three decades. At 5.0 nM IC50 in SK-N-MC cells, the compound is genuinely potent, and the azabicyclo[3.1.0]hexane scaffold with its three defined stereocenters gives you selectivity you dont get from sarcosine or D-serine. Mechanistically, this is probably the cleanest GlyT1 probe the field has produced.

The Phase II result (NCT02832037) was the thing that made people pay attention. A standardized effect size of 0.34 on the MCCB composite at 10 mg isn’t a throwaway signal. Honestly, in a space where cognitive endpoints in schizophrenia almost never move, 0.34 is remarkable. The qEEG substudy showed target engagement consistent with the occupancy modeling. There was a dose-response that made pharmacological sense, tracking the inverted-U relationship the preclinical team had flagged early. We liked this compound going into Phase III.

And then the CONNEX programme landed. 1835 patients across three trials, well-powered, and the Phase II signal did not replicate. This is where the story gets genuinely complicated for the research community. The failure isn’t obviously interpretable as “the mechanism is wrong.” Bitopertin, Roche’s GlyT1 inhibitor, failed Phase III earlier, which should have been a warning sign. The open question now is whether the NMDA hypofunction/GlyT1 approach is fundamentally broken for CIAS, or whether both programmes had endpoint selection, patient stratification, and concomitant antipsychotic confounds that swamped a real but modest effect. The field hasn’t reached consensus, and thats actually an interesting scientific problem.

What we think now: as a clinical candidate for CIAS, iclepertin is done. But as a probe compound, it’s still the most potent and selective small-molecule GlyT1 inhibitor in the public literature, and any investigator working on glutamate biology, NMDA receptor pharmacology, or the synaptic glycine co-agonist system has legitimate reasons to reach for it. The inverted-U dose-response data is useful for bench work on its own terms. You can use this compound to interrogate GlyT1 occupancy thresholds in rodent cognitive models in ways sarcosine or D-serine simply don’t allow.

What we don’t like: two large Phase III failures for the same mechanistic class is a heavy prior against the clinical translation story. The path from GlyT1 occupancy to durable cognitive benefit in schizophrenia populations looks harder than the preclinical models ever suggested, and that’s a problem the whole glutamate field is still working through. Score reflects the probe value as real, the clinical value as spent.

Novelty

38

Mechanism promise

45

In-category differentiation

47

Evidence quality

62

Translational signal

35

Research bench value

55

Rationale Iclepertin is the most potent and selective small-molecule GlyT1 inhibitor available and produced the strongest Phase II CIAS signal in its class (ES 0.34 on MCCB), but the CONNEX Phase III programme across 1835 patients failed to replicate; it scores as a serious research probe with intact mechanistic rationale, but the translational path for the primary clinical indication is broken and the GlyT1/CIAS hypothesis is now two-for-two in Phase III failure.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective glycine transporter type 1 (GlyT1) inhibitor for glutamatergic NMDA receptor enhancement

A potent azabicyclo[3.1.0]hexane methanone GlyT1 inhibitor developed by Boehringer Ingelheim to normalize glutamatergic hypofunction in schizophrenia, distinguished by positive Phase II cognitive efficacy signals (standardized effect size 0.34 on MCCB at 10 mg) and subsequent failure to replicate in the 1835-patient Phase III CONNEX programme.

Abstract

Iclepertin (BI 425809) is a potent and selective inhibitor of glycine transporter type 1 (GlyT1) with an IC50 of 5.0 nanomolar in human SK-N-MC cells, developed by Boehringer Ingelheim for the treatment of cognitive impairment associated with schizophrenia (CIAS). The compound is an orally bioavailable azabicyclo[3.1.0]hexane methanone bearing two trifluoromethyl groups and a methylsulfonyl substituent, with three defined stereocenters and a molecular weight of 512.42 g/mol. By blocking the reuptake of glycine from the synaptic cleft into astrocytes and presynaptic terminals, iclepertin increases synaptic glycine concentration at the glycine-B co-agonist site of the N-methyl-D-aspartate (NMDA) receptor, thereby enhancing glutamatergic neurotransmission. This mechanism addresses the NMDA receptor hypofunction hypothesis of schizophrenia, which posits that reduced glutamatergic signaling contributes to the cognitive deficits observed in the disorder.

Pharmacokinetically, iclepertin exhibits a terminal half-life of 34 to 59 hours, supporting once-daily oral dosing with steady-state conditions achieved by day 6. Oral bioavailability is approximately 72 percent for a 25 mg tablet under fasted conditions. The compound is metabolized predominantly (90 percent or greater) by cytochrome P450 3A4, rendering it sensitive to strong CYP3A4 inhibitors (approximately 6-fold AUC increase with itraconazole) and inducers (approximately 90 percent AUC reduction with rifampicin). In Phase I studies, oral administration of 10 mg produced a dose-dependent approximately 50 percent increase in cerebrospinal fluid glycine levels, confirming central target engagement.

The Phase II clinical programme produced divergent results across indications. In a 509-patient randomized, double-blind, placebo-controlled trial in schizophrenia (NCT02832037), iclepertin at 10 mg once daily for 12 weeks produced a statistically significant improvement on the MATRICS Consensus Cognitive Battery overall composite T-score, with an adjusted mean difference of 1.98 points and a standardized effect size of 0.34 versus placebo. However, a parallel 610-patient Phase II trial in mild-to-moderate Alzheimer’s disease dementia (NCT02788513) failed to demonstrate any dose-response relationship on the ADAS-Cog11 primary endpoint. A subsequent Phase II trial combining iclepertin with computerized cognitive training (NCT03859973, n=200) also failed to meet its primary endpoint. The compound received United States Food and Drug Administration Breakthrough Therapy Designation for CIAS in May 2021. In January 2025, Boehringer Ingelheim reported that the Phase III CONNEX programme, comprising three replicate randomized controlled trials enrolling 1835 patients across 338 sites in 41 countries with 26 weeks of treatment at 10 mg once daily, failed to meet its primary or key secondary endpoints (pooled MCCB adjusted mean difference 0.127, 95 percent confidence interval negative 0.396 to 0.650, p=0.63). Iclepertin was well tolerated across all trials, with adverse event rates numerically similar to or lower than placebo. The compound is not approved in any jurisdiction.

This monograph reviews the chemistry and synthesis of iclepertin; the molecular pharmacology of GlyT1 inhibition and the NMDA receptor enhancement mechanism; the comprehensive pharmacokinetic characterization including CYP3A4 drug-drug interactions; preclinical efficacy in MK-801 deficit and social recognition models; the complete clinical evidence base across schizophrenia, Alzheimer’s disease, and cognitive training paradigms; reconstitution, sourcing, and handling considerations; adverse event and safety signals; and a comparative assessment of five alternative NMDA-enhancing or GlyT1-targeting compounds (bitopertin, sarcosine, D-serine, PF-03463275, luvadaxistat) against iclepertin on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1648Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 22, 2026
Lanicemine

Our opinion on this compoundNiche research probe

48/100

A failed TRD program whose clinical demise sharpens rather than closes the NMDA trapping-mechanism research question

Look, lanicemine is one of those compounds where the failure is almost as interesting as the success would have been. Originally synthesized by Astra as a neuroprotectant under the designation AR-R 15896AR, it spent the late 1990s and early 2000s working through stroke trials before tolerability at the high concentrations needed for neuroprotection killed that program. The repositioning to treatment-resistant depression made obvious sense after Zarate and colleagues published the 2006 ketamine data: if ketamine’s rapid antidepressant effect runs through NMDA channel blockade, maybe you can get the same signal without the dissociative burden by using a low-trapping blocker instead.

That’s the core mechanistic bet. Lanicemine traps in the NMDA channel pore at roughly 54% versus ketamine’s 86%. The trapping hypothesis holds that high trapping drives both the psychotomimetic effects and, critically, the downstream plasticity cascade, so a low-trapping blocker was designed to ask whether you need the trap to get the antidepressant signal. The NIMH single-infusion crossover trial by Zarate et al. came back positive. Phase IIa looked encouraging. Then the 302-patient Phase IIb (Study 9, NCT00781742) did not separate from placebo on the primary endpoint, and AstraZeneca terminated the program.

What makes this compound worth keeping in the library is precisely what the failure revealed. The relationship between channel trapping, psychotomimetic liability, and antidepressant efficacy is still not resolved. Lanicemine is the best-characterized low-trapping reference compound with real clinical PK/PD characterization, and it gives investigators a reasonably clean handle on use-dependent, voltage-dependent NMDA channel blockade in a context where the dissociative confound is minimal. If you’re trying to understand what ketamine’s downstream AMPA potentiation, mTOR activation, or BDNF release actually requires of the block, lanicemine is a tool that lets you ask that question with some confidence about what’s happening at the channel level. The Ki of 0.5 to 2.1 micromolar at NR2A- and NR2B-containing receptors is workable for in vitro dissection.

We dont think lanicemine has a clinical future. The Phase IIb failure against a well-powered, well-designed trial is the dominant signal, and esketamine’s approval absorbed the commercial oxygen in the NMDA-for-depression space. The adjunctive design in the NCT01482221 protocol showed more promise than the monotherapy approach, but thats a narrow basis for continued development against a clean Phase IIb negative.

What this compound is actually good for: NMDA receptor biology, trapping-mechanism dissection, psychotomimetic liability modeling, and comparative pharmacology against ketamine, memantine, and newer entrants like dextromethorphan. The clinical failure sharpens the research questions more than it closes them. At the bench level, honestly, that counts for something.

Novelty

35

Mechanism promise

58

In-category differentiation

52

Evidence quality

50

Translational signal

30

Research bench value

65

Rationale The Phase IIb primary-endpoint failure is the dominant clinical signal and the translational score reflects it, but lanicemine is the best-characterized low-trapping NMDA channel blocker with real human PK/PD data and remains a genuinely useful probe for dissecting what ketamine’s channel-trapping actually requires for downstream plasticity signaling. Scored as niche-probe: clinical future is essentially nil, bench value is real.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Low-trapping, non-competitive N-methyl-D-aspartate receptor channel blocker

A phenylethylamine NMDA channel blocker distinguished from ketamine by low channel trapping (54% versus 86%), originally developed by AstraZeneca as a neuroprotectant for acute ischaemic stroke (AR-R 15896AR), repositioned for treatment-resistant depression following the discovery of ketamine’s rapid antidepressant properties, and terminated after a 302-patient Phase IIb trial failed to separate from placebo.

Abstract

Lanicemine (AZD6765, formerly AR-R 15896AR) is a low-trapping, non-competitive N-methyl-D-aspartate (NMDA) receptor channel blocker that binds within the ion channel pore of NR2A- and NR2B-containing NMDA receptor complexes with micromolar affinity (Ki 0.5 to 2.1 micromolar; IC50 approximately 10 micromolar at resting membrane potential in rat cortical neurons). The compound is distinguished from the prototypical NMDA channel blocker ketamine by substantially lower channel trapping (54% versus 86%), a property that confers use-dependent, voltage-dependent blockade with preferential activity on tonically active neurons and minimal psychotomimetic liability. Originally synthesized by Astra (later AstraZeneca) as a neuroprotectant designated AR-R 15896AR, the compound advanced through Phase II trials for acute ischaemic stroke in 175 and 103 patients respectively before the stroke program was terminated owing to tolerability limitations at the high doses required for neuroprotective plasma concentrations. Following the demonstration of rapid antidepressant properties of ketamine in treatment-resistant major depressive disorder by Zarate and colleagues, AstraZeneca repositioned the compound for depression under the designation AZD6765 and the International Nonproprietary Name lanicemine.

The depression clinical program comprised four principal studies. A single-infusion crossover trial at the National Institute of Mental Health (n=22, 150 mg intravenous) demonstrated rapid but transient antidepressant effects (d=0.40 on the Montgomery-Asberg Depression Rating Scale) with no psychotomimetic effects compared to placebo. A Phase IIB repeated-dosing trial (n=152, three infusions per week for three weeks) demonstrated sustained antidepressant efficacy at 100 mg (MADRS change minus 5.5 versus placebo, p=0.006) with minimal dissociative adverse events. However, a larger Phase IIb trial (n=302, 49 centers, four countries, 15 infusions over 12 weeks) at 50 mg and 100 mg doses adjunctive to ongoing antidepressant treatment failed to separate from placebo on the primary endpoint (MADRS change at week 6) or any secondary measure, resulting in program termination by AstraZeneca in 2013.

Pharmacokinetics following intravenous administration are described by a two-compartment model with low systemic clearance (8.1 to 9.4 L/h), a terminal half-life of 10 to 16 hours, and predominantly urinary elimination (93.8% of a radiolabeled dose); the compound does not inhibit or induce CYP3A4 in vivo. Preclinical pharmacology demonstrates antidepressant-like activity in the tail suspension test (1 mg/kg, dependent on PI3K/Akt/mTOR/GSK3-beta signaling), reversal of chronic unpredictable mild stress-induced behavioral and neurometabolic deficits, and neuroprotection comparable to MK-801 in the intrastriatal malonate model without the behavioral side effects of high-trapping NMDA antagonists. The compound is positioned within a comparator landscape that includes esketamine (approved), dextromethorphan/bupropion (approved), rapastinel (Phase 3 failed), memantine (failed for depression), and rislenemdaz (pilot only). Lanicemine is not approved for any indication. It is available as a research-grade compound for in vitro and in vivo investigation; investigators should obtain analytical confirmation of identity and purity on every lot.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1655Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 22, 2026
LM22B-10

Our opinion on this compoundNovel, promising

58/100

Dual TrkB/TrkC small-molecule probe with impressive preclinical breadth but a contested mechanism and thin independent evidence base

Look, the neurotrophin field has needed a credible small-molecule dual TrkB/TrkC tool for a long time. Recombinant BDNF and NT-3 don’t cross the blood-brain barrier at useful concentrations, and 7,8-dihydroxyflavone activates TrkB reasonably well but ignores TrkC entirely. LM22B-10, identified by Yang, Massa, and Longo at Stanford through in silico BDNF loop-domain pharmacophore screening combined with low-throughput neuronal survival assays, is the first small molecule reported to co-activate both receptors, with TrkB EC50 of approximately 1.8 micromolar, TrkC EC50 of approximately 2.5 micromolar, and neuronal survival EC50 in the 200 to 300 nanomolar range that the discovery group claims exceeds recombinant BDNF and NT-3 individually and in combination. That’s a real pitch, and the triarylmethane scaffold is genuinely novel for this receptor class.

The preclinical breadth is the other thing that gets our attention. In R6/2 and Q140 Huntington’s disease mouse models, the compound reduced intranuclear huntingtin aggregates, attenuated medium spiny neuron degeneration, suppressed microglial activation, and improved motor performance. In a rat controlled cortical impact model, 10 mg/kg intraperitoneal reduced cortical cell death roughly 59 percent and increased hippocampal doublecortin-positive neurogenesis approximately 65 percent, with concurrent behavioral improvement. Corneal nerve regeneration in both healthy and diabetic mouse wound models via topical eye drops adds a genuinely distinct indication. The oral-bioavailability-optimized derivative PTX-BD10-2 from PharmatrophiX then showed prevention of cholinergic atrophy and restoration of hippocampal LTP in late-stage hAPPLond/Swe Alzheimer’s mice. Aging, neurodegeneration, acute neurotrauma, peripheral neuropathy: four distinct indication spaces with preclinical signal is not nothing.

Here’s the thing though: an independent validation study using microscale thermophoresis reported Kd approximately 83 micromolar at the TrkB extracellular domain and failed to induce TrkB, Akt, or ERK1/2 phosphorylation in conventional blotting assays. That directly contradicts the original characterization, and the discrepancy has not been resolved. A 2025 Journal of Medicinal Chemistry review proposed that LM22B-10 and related putative Trk agonists may function as positive allosteric modulators at the transmembrane domain rather than classical orthosteric agonists. That model might actually account for the biology better than the original story, but it means the mechanism claim the compound was built on remains formally contested.

For investigators running a TrkB/TrkC signaling program, LM22B-10 is still one of very few BBB-permeant small-molecule probes producing a dual-receptor functional effect in vivo, and resolving whether it’s orthosteric, allosteric, or something more indirect is a legitimately important open question. The bench value is real. What we don’t like: no clinical trials, no IND, no human pharmacokinetic data, and the evidence base outside the Stanford/PharmatrophiX ecosystem is thin enough that sourcing and batch-to-batch consistency become investigator problems, not vendor problems. The translational arrow is long. Dont treat the preclinical breadth as a substitute for independent replication of the core pharmacology claim first.

Novelty

75

Mechanism promise

68

In-category differentiation

70

Evidence quality

35

Translational signal

28

Research bench value

62

Rationale LM22B-10 earns its novelty marks as the first small molecule co-activating both TrkB and TrkC with BBB permeability, producing signal across aging, Huntington’s disease, TBI, corneal neuropathy, and an AD derivative model; however, a failed independent validation at 83 micromolar Kd and a 2025 JMedChem reinterpretation of its mechanism as transmembrane allosteric rather than orthosteric represent unresolved liabilities that meaningfully compress evidence quality and translational confidence.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Non-peptide triarylmethane small-molecule TrkB/TrkC neurotrophin receptor co-activator

A triarylmethane neurotrophin mimetic identified through in silico screening of BDNF loop-domain pharmacophores, distinguished as the first small molecule to co-activate TrkB and TrkC receptors with preclinical efficacy across aging, Alzheimer’s disease, Huntington’s disease, traumatic brain injury, and corneal neuropathy models.

Abstract

LM22B-10 (CAS 342777-54-2) is a non-peptide, blood-brain barrier permeant, triarylmethane small molecule that co-activates tropomyosin-related kinase B (TrkB) and tropomyosin-related kinase C (TrkC) neurotrophin receptors. It was identified by Yang, Massa, and Longo at Stanford University through in silico screening with a brain-derived neurotrophic factor (BDNF) loop-domain pharmacophore, coupled with low-throughput neuronal survival screening, and was first reported in Neuropharmacology in 2016. LM22B-10 is distinguished from prior small-molecule Trk ligands, which typically activate a single receptor subtype, by its dual activation of TrkB (EC50 approximately 1.8 micromolar) and TrkC (EC50 approximately 2.5 micromolar), producing neurotrophic activity with an EC50 for neuronal survival of 200 to 300 nanomolar that exceeds the effects of recombinant BDNF and neurotrophin-3 (NT-3), individually and in combination, in hippocampal neuronal assays. The compound selectively activates TrkB and TrkC without engaging TrkA, and drives downstream Akt and ERK1/2 signaling in vitro and in vivo. Preclinical studies in aged mice demonstrated that LM22B-10 activates hippocampal and striatal TrkB and TrkC signaling, increases dendritic spine density, and supports neuronal integrity. In mouse models of Huntington’s disease (R6/2 and Q140), the compound reduced intranuclear huntingtin aggregates, dendritic spine loss, microglial activation, and degeneration of medium spiny neurons while improving motor performance. In a rat controlled cortical impact model of traumatic brain injury, LM22B-10 at 10 mg/kg intraperitoneal reduced cortical cell death by approximately 59 percent and increased hippocampal doublecortin-positive neurogenesis by approximately 65 percent, with concurrent improvement in spatial memory and anxiety-related behavior in injured animals. The compound has also demonstrated corneal nerve regeneration in both healthy and diabetic mouse wound models when delivered as topical eye drops. A derivative, PTX-BD10-2, was developed by PharmatrophiX with improved oral bioavailability and has demonstrated prevention of cholinergic neuron atrophy, restoration of hippocampal long-term potentiation, and normalization of synaptic function in late-stage Alzheimer’s disease mouse models (hAPPLond/Swe) following chronic oral dosing. The mechanism of TrkB/TrkC activation by LM22B-10 is not without controversy. An independent validation study using microscale thermophoresis reported weak binding to the TrkB extracellular domain (Kd approximately 83 micromolar) and failure to induce TrkB, Akt, or ERK1/2 phosphorylation in conventional blotting assays, results that contrast with the original characterization. A 2025 review in the Journal of Medicinal Chemistry proposed that LM22B-10 and related putative Trk agonists may function as positive allosteric modulators binding the transmembrane domain rather than as classical orthosteric agonists. The discrepancy remains unresolved and constitutes a significant open question in the field. LM22B-10 has not entered clinical trials; it remains a preclinical research tool. This monograph reviews the chemistry, dual-receptor pharmacology, preclinical evidence base across disease models, the mechanistic controversy, sourcing and handling considerations, and a comparative assessment of five neurotrophin receptor ligands against LM22B-10 on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1640Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 22, 2026
Navacaprant

Our opinion on this compoundNovel, promising

63/100

Cleanest KOR antagonist in clinical testing, real anhedonia signal, but Phase 3 null is hard to explain away

Look, the kappa opioid receptor story for depression is genuinely interesting biology, and navacaprant is the cleanest version of the hypothesis we’ve seen in a clinical setting. The KOR system is deeply wired into stress circuits, anhedonia, and dysphoria. Blocking it isn’t just another monoamine trick; it’s targeting a specific neurobiological substrate that standard antidepressants don’t touch. That mechanistic angle is real, and the compound’s selectivity profile makes it the best available probe for it.

The pharmacology is unusually clean. 1.2 nM potency at KOR in native VTA dopamine neurons, 300-fold selectivity over mu, 340-fold over delta, no detectable agonist activity at any opioid subtype in vitro. The problems that killed JDTic (c-JNK activation, cardiac toxicity in humans), made nor-BNI impractical (weeks-long receptor occupancy), and muddied aticaprant’s mechanism (partial mu/delta activity in native tissue electrophysiology) simply don’t apply here. The PET occupancy work is also genuinely useful: a single 160 mg dose achieving roughly 90 percent KOR occupancy, with the 80 mg clinical dose projected to maintain that at steady state. That kind of pharmacokinetic-pharmacodynamic clarity is exactly what you want in a research probe.

Here’s the thing though. The clinical picture is complicated. The Phase 2a data from Mathew et al. 2025 has a real signal buried in it: in the moderate-to-severe MDD subgroup, response rates were 45.5 percent versus 24.1 percent for placebo, and an NNT of 5 for response is genuinely meaningful. Anhedonia-specific improvements on the SHAPS are mechanistically consistent with what you’d predict from KOR blockade. But the primary endpoint failed. And then KOASTAL-1 failed badly: both arms reported identical 12.5-point MADRS reductions, p equals 0.993. Thats not a near-miss, that’s a null, and a large-N null at that.

We think the compound is probably doing something real in a specific subpopulation, and the failure mode is patient selection rather than mechanism failure. The exploratory differential response in female participants in KOASTAL-1 and the protocol modifications for KOASTAL-2 and KOASTAL-3 suggest Neumora’s team agrees. Whether that stratification story holds up in 2026 matters enormously for any translational read. For now, the human evidence is inconsistent enough that we score it conservatively.

What we still like: navacaprant is the only available selective reversible KOR antagonist with Phase 3-grade pharmacokinetic characterization and confirmed brain penetrance in humans. For anyone studying stress-induced anhedonia models, dynorphin signaling, or KOR circuit biology in affective states, this is the probe you’d reach for over any alternative. The tolerability profile is also a research asset: no weight gain, no sexual dysfunction, fewer treatment-emergent adverse events than placebo in Phase 2. That matters for study design and for modeling the KOR system without the confounds that follow legacy compounds in this class.

Novelty

68

Mechanism promise

68

In-category differentiation

72

Evidence quality

56

Translational signal

44

Research bench value

68

Rationale Navacaprant represents best-in-class pharmacology within the KOR antagonist class, with a mechanistically coherent anhedonia signal in Phase 2 and genuine probe utility for stress-circuit biology, but the KOASTAL-1 null (p=0.993, identical 12.5-point reductions in both arms) meaningfully depresses translational scores and prevents placement in the novel-frontier tier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective, reversible kappa opioid receptor antagonist with no agonist activity at kappa, mu, or delta opioid receptors

A fluorinated quinoline-oxadiazole kappa opioid receptor antagonist discovered at Scripps Research and advanced through Phase 3 clinical trials for major depressive disorder, distinguished from earlier KOR antagonists by full receptor antagonism without mu or delta cross-reactivity, rapid reversibility, and a favorable tolerability profile in controlled clinical studies.

Abstract

Navacaprant (BTRX-335140, NMRA-140, CYM-53093) is a potent, highly selective, and reversible antagonist of the kappa opioid receptor (KOR) under clinical development for the treatment of major depressive disorder (MDD). The compound was discovered in collaboration between Scripps Research faculty members Hugh Rosen and Edward Roberts and was advanced through clinical development first by BlackThorn Therapeutics and subsequently by Neumora Therapeutics. Navacaprant blocks the KOR with an IC50 of 1.2 nanomolar in native ventral tegmental area dopamine neurons and 29 nanomolar in recombinant CHO-K1 cells, with approximately 300-fold selectivity over the mu opioid receptor and greater than 340-fold selectivity over the delta opioid receptor. The compound exhibits no detectable agonist activity at any opioid receptor subtype in vitro (EC50 greater than 10 micromolar) and no opioid agonist effects in vivo, including no alteration of extracellular dopamine in the nucleus accumbens at oral doses up to 100 mg/kg in rats. The pharmacological profile differentiates navacaprant from earlier KOR antagonists: unlike JDTic (which activates c-Jun N-terminal kinase and produced cardiac toxicity in humans), nor-binaltorphimine (which has an impractically long duration of action), and aticaprant (which partially blocks mu and delta opioid receptor responses in native tissue electrophysiology), navacaprant combines full KOR antagonism with rapid reversibility, clean selectivity, and no off-target opioid effects. In a Phase 1 program in healthy volunteers, navacaprant demonstrated favorable pharmacokinetics across single oral doses of 5 to 240 mg and multiple daily doses of 20 to 160 mg for 10 days, with good tolerability and no serious adverse events. A positron emission tomography receptor occupancy study confirmed brain KOR engagement, with a single 160 mg dose producing approximately 90 percent occupancy and pharmacokinetic-pharmacodynamic modeling projecting approximately 90 percent occupancy at steady state with 80 mg once daily. In a Phase 2a randomized, double-blind, placebo-controlled trial in 204 adults with MDD (Mathew et al. 2025), navacaprant 80 mg once daily for 8 weeks did not meet the primary endpoint in the full efficacy population (Hamilton Depression Rating Scale least-squares mean difference versus placebo of negative 1.7 points, p equals 0.121), but demonstrated statistically significant improvements in the moderate-to-severe MDD subgroup on both depressive symptoms and anhedonia as measured by the Snaith-Hamilton Pleasure Scale, with response rates of 45.5 percent versus 24.1 percent for placebo (number needed to treat equals 5) and remission rates of 26.1 percent versus 10.8 percent (number needed to treat equals 7). Fewer treatment-emergent adverse events occurred in the navacaprant group than in the placebo group, and no serious adverse events, weight gain, or sexual dysfunction were reported with navacaprant. In Phase 3, the KOASTAL-1 trial (n equals 383) failed to demonstrate separation from placebo on the Montgomery-Asberg Depression Rating Scale primary endpoint, with both treatment arms reporting identical 12.5-point reductions (p equals 0.993); exploratory subgroup analyses suggested a differential response in female participants. The KOASTAL-2 and KOASTAL-3 Phase 3 trials were paused for protocol modifications and are expected to report data in 2026. This monograph reviews the chemistry and structural pharmacology of navacaprant; the molecular pharmacology including receptor binding, selectivity, and electrophysiological characterization; the available pharmacokinetic data; the preclinical pharmacology in stress and cognitive models; the clinical evidence base including the Phase 2 and Phase 3 programs; sourcing and quality verification; handling considerations; stack interactions; adverse events; and a comparative assessment of five kappa opioid receptor candidates (aticaprant, buprenorphine-samidorphan, JDTic, nor-binaltorphimine, and PF-04455242) against navacaprant. The compound is investigational and is not approved by any regulatory authority. It is available as a research-grade preparation; investigators should obtain analytical confirmation of identity and purity on every lot.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1656Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 22, 2026
NPT520-34

Our opinion on this compoundNovel, promising

64/100

First-in-class oral TLR2 antagonist breaking alpha-synuclein feedforward loop, strong mechanism, no patient data yet

Honestly, NPT520-34 is one of the more conceptually interesting compounds we’ve reviewed in the neurodegeneration space. The core story is a feedforward loop that’s been building in the Parkinson’s literature for years: oligomeric alpha-synuclein activates TLR2 on microglia and neurons, TLR2 activation suppresses autophagy through the AKT/mTOR axis, which lets alpha-synuclein accumulate further, which drives more TLR2 signaling. Neuropore’s compound interrupts that cycle at the TLR2 node. That’s not a trivial target choice. Postmortem PD brain data shows TLR2 neuronal expression climbing from roughly 3 percent in control tissue to 47 percent in late-stage disease, which is the kind of biological anchor that justifies building a selective antagonist for it. The dual pharmacology is genuinely elegant: you clear the aggregates and suppress the inflammation from the same single target.

The preclinical package in the mThy1-alpha-synuclein Line 61 transgenic model is solid for a small-molecule CNS program. Daily dosing at 0.5 to 10 mg/kg produced dose-dependent reductions in total alpha-synuclein in the neocortex (P less than 0.0001 at the higher doses), reductions in proteinase K-resistant synuclein in the striatum, and functional improvements in grip strength and gait analysis. The acute LPS-challenge data showing suppression of IL-6, TNF-alpha, and MIP-2 adds to the anti-inflammatory story. Mouse PK confirms brain penetrance in a dose-linear fashion, and the oral bioavailability is essential for any realistic chronic neurodegeneration program.

Phase 1 (NCT03954600) enrolled 49 healthy volunteers across single and multiple ascending doses up to 500 mg/day for 14 days. Dose-linear PK, half-life around 8 hours, no serious adverse events, headache as the primary complaint. That’s a clean safety readout. The FDA orphan designation for ALS in August 2019 signals regulators found the mechanistic rationale credible. But we have to be honest about where the evidence stops: the Phase 1 data remains unpublished in a peer-reviewed journal, theres no registered Phase 2 in PD or ALS patients, and essentially all the preclinical data comes from within the Neuropore program itself. The Line 61 model is well-regarded as a synuclein overexpression tool, but transgenic PD models have a stubborn history of poor clinical translation.

What we like here is the mechanism specificity and the oral brain-penetrant profile. As a research tool for TLR2-mediated neuroinflammation in synucleinopathy models, this is genuinely useful in a way that most peptide candidates are not. The comparison field is worth noting: anle138b is still preclinical-only, prasinezumab showed signal only in fast-progressors, nilotinib essentially failed its PD trials. NPT520-34 occupies a distinct mechanistic lane. What we dont like is the development pause. No public Phase 2 timeline, a silent publication record on the clinical data, and without patient efficacy numbers the translational signal stays entirely mechanistic. Promising first-in-class compound, real questions about whether anyone is still actively pushing it forward.

Novelty

75

Mechanism promise

78

In-category differentiation

74

Evidence quality

42

Translational signal

40

Research bench value

62

Rationale High novelty and mechanism scores reflect first-in-class TLR2 antagonism with a well-defined feedforward-loop rationale and confirmed oral CNS penetrance; evidence and translational scores are capped by single-consortium preclinical data, unpublished Phase 1 results, and a complete absence of Phase 2 patient efficacy data.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Orally bioavailable, brain-penetrant small molecule toll-like receptor 2 (TLR2) antagonist with dual activity promoting autophagic clearance of alpha-synuclein aggregates and attenuating neuroinflammation

A first-in-class small molecule TLR2 antagonist developed by Neuropore Therapies for Parkinson’s disease and amyotrophic lateral sclerosis, acting through dual suppression of neuroinflammation and enhancement of autophagic protein clearance in neurodegenerative synucleinopathies.

Abstract

NPT520-34 is an orally bioavailable, brain-penetrant small molecule antagonist of toll-like receptor 2 (TLR2), developed by Neuropore Therapies, Inc. (San Diego, California) as a disease-modifying therapeutic candidate for Parkinson’s disease and amyotrophic lateral sclerosis. The compound was identified through cell-based assays of alpha-synuclein clearance and subsequently characterized for two complementary pharmacological actions: enhancement of autophagic clearance of neurotoxic protein aggregates and direct attenuation of neuroinflammation mediated by microglia and astrocytes [1]. The mechanistic rationale targets TLR2, a pattern-recognition receptor of the innate immune system that is upregulated approximately twofold in postmortem Parkinson’s disease brain tissue, with neuronal TLR2 expression increasing from approximately 3 percent of neurons in control brain to 47 percent in late-stage disease [3]. Neuron-released oligomeric alpha-synuclein acts as an endogenous agonist of TLR2, driving a feedforward loop of TLR2 activation, AKT/mTOR-dependent autophagy inhibition, alpha-synuclein accumulation, and neuroinflammatory cytokine release [2, 4]. NPT520-34 is proposed to interrupt this cycle through TLR2 antagonism. In the principal preclinical study, daily intraperitoneal administration of NPT520-34 at 0.5 to 10 mg/kg to mThy1-alpha-synuclein (Line 61) transgenic mice for one or three months produced statistically significant reductions in total alpha-synuclein in the neocortex (P < 0.0001 at 5 and 10 mg/kg), reductions in proteinase K-resistant alpha-synuclein in the striatum (P < 0.05 at 1, 5, and 10 mg/kg), and reductions in the neuroinflammation markers TSPO and TLR2 mRNA, with concurrent improvements in grip strength (P < 0.001 to P < 0.0001), forelimb clasping, and computerized gait analysis parameters [1]. In a separate acute lipopolysaccharide-challenge model, a single dose of NPT520-34 reduced plasma levels of pro-inflammatory cytokines including interleukin-6, tumor necrosis factor alpha, and macrophage inflammatory protein 2 [1]. In vitro, NPT520-34 increased LC3 puncta accumulation in B103 neuroblastoma cells at concentrations of 1 to 10 micromolar, consistent with autophagy induction [1]. Mouse pharmacokinetic studies demonstrated dose-dependent linear exposures in both plasma and brain tissue, confirming blood-brain barrier penetration [1]. In a Phase 1 randomized, double-blind, placebo-controlled trial (NCT03954600) enrolling 49 healthy adult volunteers, single ascending oral doses from 125 to 1000 mg and multiple ascending doses of 250 to 500 mg daily for 14 days demonstrated dose-linear pharmacokinetics with an elimination half-life of approximately 8 hours [7, 9, 11]. NPT520-34 was safe and well tolerated at all doses tested, with no serious adverse events, no discontinuations, and headache as the most frequently reported adverse event [9, 11]. The U.S. Food and Drug Administration granted orphan drug designation for the treatment of amyotrophic lateral sclerosis in August 2019 [10]. As of the date of this monograph, no Phase 2 trials in patients with Parkinson's disease or amyotrophic lateral sclerosis have been registered, and peer-reviewed publication of the Phase 1 pharmacokinetic and safety data remains pending. Investigators should treat the available clinical data as preliminary. This monograph reviews the chemistry, the TLR2-mediated mechanism of action in the context of the broader synucleinopathy literature, the preclinical pharmacology across neurodegenerative disease models, the Phase 1 clinical data, and a comparative assessment of five alternative alpha-synuclein-targeting therapeutic candidates. The compound is not approved for any indication in any jurisdiction and is available only for research use.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1651Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 22, 2026
Omecamtiv Mecarbil

Our opinion on this compoundNovel, promising

74/100

First-in-class cardiac myosin activator with real Phase 3 signal, marred by modest effect size and FDA rejection

Look, there’s a case to be made that omecamtiv mecarbil is one of the most structurally interesting small molecules in cardiovascular pharmacology right now. Not because it works better than what we have, but because of what it does differently.

Every inotrope before this either raises intracellular calcium (catecholamines, digoxin) or sensitizes the sarcomere to calcium it already has (levosimendan). Omecamtiv does neither. It binds an allosteric pocket on the cardiac myosin S1 domain and stabilizes the lever arm in a pre-powerstroke conformation, accelerating phosphate release from the ATPase cycle and increasing the number of myosin heads engaged with actin during systole. Cytokinetics resolved the binding site by X-ray crystallography at 2.45 Angstrom resolution, so we’re not speculating about the mechanism here. The converter domain rotates roughly 15 degrees, the relay helix shifts, and selectivity for cardiac over skeletal and smooth muscle myosin is rationalized by divergent converter residues across isoforms. Thats a well-characterized mechanism for something this new to clinical pharmacology.

The GALACTIC-HF trial (n = 8,256) gave us the clinical picture: a statistically significant reduction in the primary composite of cardiovascular death or heart failure event (hazard ratio 0.92, p = 0.03), concentrated heavily in the subgroup with LVEF at or below 22% (HR 0.83). That’s real. The NT-proBNP reductions and systolic ejection time prolongation as a pharmacodynamic marker have been replicated across phases 1 through 3. What we don’t like: cardiovascular death alone wasn’t reduced, the FDA issued a Complete Response Letter in February 2023, and METEORIC-HF (n = 276) found no improvement in peak exercise capacity over 20 weeks. The confirmatory COMET-HF trial is ongoing in the severe-EF subgroup with expected completion in 2028, which means this mechanism is still genuinely unresolved at the regulatory level.

For bench-scale investigators in cardiac mechanobiology, this compound is close to indispensable. You can use it to dissect cross-bridge kinetics independent of calcium transients, compare sarcomere mechanics across myosin isoforms, and probe the relationship between systolic mechanics and cardiac remodeling without the confounders you get from catecholamine-based tools. Oral bioavailability around 93%, a well-characterized decarbamylation metabolism pathway, and no QTc liability make experimental design tractable in a way most inotropic probes aren’t.

The 74 reflects genuine novelty and mechanistic clarity alongside a translational picture thats more qualified than early enthusiasm suggested. This isn’t a platform winner yet. It’s a first-mover in a class where the full biology is still being worked out, and COMET-HF data could move this score meaningfully in either direction.

Novelty

70

Mechanism promise

80

In-category differentiation

82

Evidence quality

72

Translational signal

62

Research bench value

75

Rationale Differentiation and mechanism scores drive this up: no other compound touches cardiac myosin this way, and the 2.45 Angstrom crystal structure makes the allosteric pharmacology unusually tractable for bench investigators. The modest GALACTIC-HF hazard ratio (0.92), negative METEORIC-HF exercise result, and February 2023 FDA CRL limit the translational and evidence scores, landing the overall at 74.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

First-in-class selective small-molecule cardiac myosin activator

A selective allosteric activator of the cardiac myosin heavy chain discovered at Cytokinetics through high-throughput sarcomere screening, distinguished from all prior inotropes by direct augmentation of actin-myosin cross-bridge formation independent of intracellular calcium signaling, with a positive Phase 3 cardiovascular outcomes signal in heart failure with reduced ejection fraction concentrated among patients with the most severely depressed systolic function.

Abstract

Omecamtiv mecarbil (CK-1827452, AMG 423) is a first-in-class selective small-molecule activator of cardiac myosin, the beta-myosin heavy chain (MYH7) motor protein of the ventricular sarcomere. Discovered at Cytokinetics, Inc. through high-throughput screening of a reconstituted calcium-responsive sarcomere assay and advanced through extensive structure-activity optimization from a poorly soluble nitro-aromatic hit compound, omecamtiv mecarbil binds an allosteric pocket on the cardiac myosin catalytic domain (S1 subfragment) that stabilizes the lever arm in a primed, pre-powerstroke conformation. The compound accelerates the rate-limiting phosphate release step of the cross-bridge cycle, increasing the number of myosin heads engaged with the actin filament during systole and prolonging the duration of force generation, without increasing intracellular calcium concentration or myocardial oxygen consumption. X-ray crystallographic studies have resolved the binding site at 2.45 Angstrom resolution, revealing interactions with the converter domain, relay helix, and N-terminal subdomain that induce a 15-degree rotation and approximately 4 Angstrom translation of the converter. Selectivity for cardiac over skeletal and smooth muscle myosin is structurally rationalized by divergent converter domain residues across isoforms. The clinical development program, spanning nine Phase 1 studies, four Phase 2 trials, and two Phase 3 trials over more than a decade, has established the pharmacodynamic signature of omecamtiv mecarbil: concentration-dependent prolongation of systolic ejection time, increased stroke volume and ejection fraction, decreased ventricular volumes, and reduced NT-proBNP, achieved without the tachycardia, hypotension, or proarrhythmic signals characteristic of catecholamine-based inotropes. The pivotal GALACTIC-HF trial (n = 8,256; NCT02929329) demonstrated a statistically significant reduction in the primary composite endpoint of cardiovascular death or first heart failure event (hazard ratio 0.92; 95% CI 0.86 to 0.99; p = 0.03), with the treatment benefit concentrated among patients with the lowest baseline ejection fractions (LVEF 22% or below: HR 0.83; 95% CI 0.73 to 0.95) and highest NT-proBNP levels. Cardiovascular death alone was not significantly reduced (HR 1.01). The METEORIC-HF trial (n = 276; NCT03759392) found no significant improvement in peak exercise capacity over 20 weeks, indicating that the cardiovascular outcomes benefit may operate through reduction of heart failure decompensation events rather than augmented peak aerobic performance. Pharmacokinetics are characterized by high oral bioavailability (approximately 93%), a terminal half-life of approximately 18 to 21 hours supporting twice-daily dosing, metabolism primarily through a decarbamylation pathway with modest CYP3A4 and CYP2D6 contributions, and balanced renal and fecal elimination. Omecamtiv mecarbil does not prolong the QTc interval at therapeutic concentrations. The compound received a Complete Response Letter from the United States Food and Drug Administration in February 2023; a confirmatory Phase 3 trial (COMET-HF) in patients with severely reduced ejection fraction is ongoing with expected completion in 2028. This monograph reviews the chemistry, structural pharmacology, comprehensive pharmacokinetic characterization, the complete clinical evidence base including positive and negative trials with subgroup analyses, the sourcing and handling considerations for research applications, and a comparative assessment of five heart failure agents against omecamtiv mecarbil on five competency standards. The compound is investigational and is not approved by any regulatory authority.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1653Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 22, 2026
Petrelintide

Our opinion on this compoundNovel, promising

68/100

A best-in-class long-acting DACRA with clean Phase 2 tolerability and an amylin mechanism genuinely orthogonal to GLP-1 biology

Look, the amylin receptor story is one of the more compelling threads in metabolic pharmacology right now, and petrelintide is probably the cleanest long-acting DACRA we’ve seen. Zealand Pharma built it carefully: a lactam bridge replaces the native disulfide, N-methylations at Gly24 and Ile26 kill the amyloid fibrillation tendency that makes wild-type amylin a handling problem, and a C20 diacid lipidation drives albumin binding to push the terminal half-life to approximately 10 days in humans. Once-weekly dosing, no amyloidogenic behavior. Thats meaningful chemistry, not cosmetic analogue work.

What we like about the mechanism is how orthogonal it is to GLP-1 biology. Amylin signals through the area postrema and nucleus tractus solitarius, a different satiety circuit from GLP-1-mediated gut-brain axes. Petrelintide hits AMY3R (EC50 0.33 nM) and the calcitonin receptor (EC50 0.32 nM) with near-identical potency. The CTR contribution isn’t fully mapped, but the balanced DACRA activity appears to underlie the lean mass preservation seen in DIO rat models. That’s a real pharmacological question, and petrelintide is a cleaner tool for asking it than anything previously available in this class.

The clinical evidence is the strongest part of the story. The Phase 1b MAD study (48 participants) showed 8.6% body weight reduction at 4.8 mg versus 1.7% with placebo after 16 weekly doses. ZUPREME-1 (NCT06662539, 493 adults with obesity, 42 weeks) met its primary endpoint across all five dose arms, reaching 10.7% mean body weight reduction at the top dose. Discontinuation rates due to adverse events were essentially placebo-level (4.8% versus 4.9%), and zero vomiting at the maximally effective dose. Compared to the GI burden typical of GLP-1 monotherapy at comparable weight-loss magnitudes, that tolerability profile is the real headline.

The $5.3 billion Roche collaboration announced in March 2025 signals commercial conviction, but whats interesting for researchers is the planned fixed-dose combination with CT-388, Roche’s dual GLP-1/GIP agonist. Petrelintide alongside a GLP-1 backbone is a direct experimental model for asking what amylin-axis activation contributes to body composition outcomes independently of incretin receptor biology.

Honest caveats: we’re looking at Phase 2 data only, single sponsor, with Phase 3 not expected to start until the second half of 2026. The DACRA space includes cagrilintide from Novo Nordisk and eloralintide from Lilly, so best-in-class isn’t locked in. The calcitonin receptor’s contribution to weight loss remains mechanistically undercharacterized. Still, petrelintide is a well-constructed probe on a mechanism that’s clearly earning serious attention, and the tolerability differentiation versus GLP-1 class compounds makes it a more practically useful research tool than the weight-loss number alone would suggest.

Novelty

70

Mechanism promise

75

In-category differentiation

68

Evidence quality

60

Translational signal

68

Research bench value

62

Rationale Petrelintide earns high novelty and mechanism scores as a genuinely distinct DACRA with sophisticated lipidation chemistry and Phase 2 ZUPREME-1 data showing 10.7% weight loss at placebo-level tolerability; evidence quality and translational scores are held back by the single-sponsor Phase 2 status and Phase 3 not yet initiated.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Long-acting lipidated human amylin analog and dual amylin/calcitonin receptor agonist (DACRA) for once-weekly subcutaneous administration

A 36-amino-acid acylated peptide engineered from human amylin with a lactam bridge, N-methylations, and C20 diacid lipidation enabling neutral-pH stability, albumin-mediated half-life extension to approximately 10 days, and once-weekly dosing for obesity and weight management.

Abstract

Petrelintide (ZP-8396) is a long-acting, subcutaneously administered analog of human amylin developed by Zealand Pharma A/S (Soborg, Denmark) as a potential foundational therapy for chronic weight management in adults with overweight and obesity. The compound is a 36-amino-acid acylated peptide bearing a lactam bridge replacement of the native Cys2-Cys7 disulfide bond, N-methylations at Gly24 and Ile26 to prevent amyloid fibrillation, strategic asparagine deletions and substitutions to eliminate deamidation-prone residues, a C-terminal hydroxyproline substitution for enhanced receptor potency, and an N-terminal C20 diacid lipidation via a gamma-glutamic acid linker that confers reversible albumin binding and a human terminal half-life of approximately 10 days, supporting convenient once-weekly dosing. Petrelintide exhibits potent balanced agonism at the amylin-3 receptor (AMY3R, EC50 0.33 nM) and the calcitonin receptor (CTR, EC50 0.32 nM) in cAMP accumulation assays, classifying it as a dual amylin and calcitonin receptor agonist (DACRA). In diet-induced obese rat models, repeated dosing produces dose-dependent reductions in food intake and body weight with preferential fat mass loss and relative preservation of lean mass. Clinical development has progressed rapidly. A first-in-human Phase 1 single ascending dose trial (NCT05096598) established safety and tolerability at subcutaneous doses of 0.04 to 2.4 mg, with a human half-life supporting weekly administration. A Phase 1b multiple ascending dose trial in 48 participants with overweight or obesity demonstrated mean body weight reductions of 4.8% (2.4 mg), 8.6% (4.8 mg), and 8.3% (9.0 mg) versus 1.7% with placebo after 16 weekly doses, with no serious or severe adverse events and gastrointestinal tolerability substantially superior to the adverse-event profiles reported for GLP-1 receptor agonist monotherapy at comparable weight-loss magnitudes. The Phase 2 ZUPREME-1 trial (NCT06662539) in 493 adults with obesity met its primary endpoint across all five dose arms, achieving up to 10.7% mean body weight reduction at 42 weeks with placebo-like tolerability, zero vomiting at the maximally effective dose, and discontinuation rates due to adverse events comparable to placebo (4.8% versus 4.9%). In March 2025, Roche entered an exclusive global collaboration and licensing agreement with Zealand Pharma valued at up to 5.3 billion US dollars to co-develop and co-commercialize petrelintide as monotherapy and in fixed-dose combination with CT-388, a dual GLP-1/GIP receptor agonist. Phase 3 initiation for chronic weight management is planned for the second half of 2026. Petrelintide is an investigational compound; its safety and efficacy have not been established by any regulatory authority. This monograph reviews the peptide chemistry, receptor pharmacology, preclinical and clinical evidence base, pharmacokinetic profile, and comparative positioning of petrelintide within the amylin receptor agonist landscape, grounded in the primary literature through May 2026. Investigators should treat all data as preliminary pending registration-quality Phase 3 results and regulatory evaluation.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1652Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 22, 2026
Reldesemtiv

Our opinion on this compoundNiche research probe

60/100

Phase 3 futility in ALS leaves a well-characterized FSTA with real probe value but no clinical future

Look, reldesemtiv is one of those compounds where the science is genuinely interesting and the clinical story is genuinely disappointing. The fast skeletal muscle troponin activator class was a real idea. Sensitize the sarcomere to calcium by slowing troponin C release, get more force output from whatever motor units are still firing in a denervated muscle. That’s a clean mechanistic hypothesis, and Cytokinetics executed the chemistry well enough to confirm it in actual human tissue.

The Phase 1 pharmacodynamic work is the bright spot. Sixteen healthy volunteers, tibialis anterior force-frequency response amplified roughly 60 percent at 10 Hz stimulation. That’s not an indirect surrogate; that’s the mechanism working in human muscle. The pharmacokinetics are well-characterized across five Phase 1 studies, dose-proportional exposure, 5-14 hour half-life, similar profiles in young and elderly. If you want to study calcium sensitization in fast skeletal fibers, this compound is pharmacologically tractable and well-understood at the bench level.

The second-generation story also matters. Tirasemtiv, the first FSTA, hit dose-limiting dizziness, nausea, weight loss, and insomnia hard enough that 34.2 percent of VITALITY-ALS participants discontinued. Reldesemtiv represents property-based optimization that genuinely improved tolerability. Thats a real accomplishment even if it didn’t change the terminal clinical outcome. The selectivity profile is also authentic: no activation of slow skeletal or cardiac troponin complexes, which is exactly what you want from a probe compound designed to isolate fast-fiber effects.

But COURAGE-ALS happened. Phase 3, 486 patients, 83 centers across 16 countries, 24 weeks. Conditional power at the second interim analysis: 8.4 percent. The primary ALSFRS-R endpoint numerically favored placebo. No preplanned subgroup favored reldesemtiv. The program was terminated for futility. That’s not ambiguous. The translational hypothesis that calcium sensitization of residual fast fibers would slow functional decline in ALS did not survive a rigorous test. The FORTITUDE-ALS Phase 2 miss on slow vital capacity (p=0.11) was a warning sign; COURAGE-ALS confirmed it.

The SMA Phase 2 data is more interesting and prevents a complete write-off. Seventy patients, statistically significant improvement in six-minute walk distance at week 4 (35.6 m, p=0.0037) and maximum expiratory pressure at week 8 in the 450 mg group. The neuronal-attenuation hypothesis may hold better in SMA than ALS for reasons related to the pattern of motor neuron loss and the stage at which fast-fiber populations are still available to sensitize. Whether that Phase 2 signal survives a larger trial is genuinely unknown.

What we think: reldesemtiv earns real points for mechanism novelty, fast-fiber selectivity, and the quality of its clinical evidence base, even though that evidence base ultimately killed the program. It’s now probe territory. For investigators studying calcium handling in fast skeletal muscle, motor unit physiology, or the FSTA class itself, this is the best-characterized compound available. The WADA listing confirms sourcing exists. Score it for what it is now: a well-made tool with a closed clinical chapter.

Novelty

62

Mechanism promise

68

In-category differentiation

65

Evidence quality

65

Translational signal

38

Research bench value

58

Rationale Reldesemtiv scores well on mechanism novelty and fast-fiber selectivity but takes a decisive translational hit from COURAGE-ALS, where conditional power fell to 8.4 percent and the primary endpoint numerically favored placebo; the SMA Phase 2 signal and clean pharmacological profile sustain moderate bench utility. Category placement as niche-probe reflects a terminated clinical program that left behind the best-available FSTA tool compound for fast skeletal muscle calcium biology.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Second-generation fast skeletal muscle troponin activator (FSTA) selective for fast skeletal muscle fibers

A next-generation fast skeletal muscle troponin activator developed by Cytokinetics to amplify skeletal muscle force output through calcium sensitization of the sarcomere, evaluated in Phase 2 and Phase 3 clinical trials in amyotrophic lateral sclerosis and spinal muscular atrophy.

Abstract

Reldesemtiv (CK-2127107) is a small-molecule fast skeletal muscle troponin activator (FSTA) that selectively binds the regulatory troponin complex in fast skeletal muscle fibers, slows the rate of calcium release from troponin C, and thereby sensitizes the sarcomere to calcium at submaximal stimulation frequencies. The compound was discovered at Cytokinetics, Inc. through property-based optimization of a high-throughput screening hit, yielding improved free exposure, in vivo muscle activation potency, and tolerability relative to the first-generation FSTA tirasemtiv, which had failed the Phase 3 VITALITY-ALS trial primarily because of dose-limiting tolerability (dizziness, nausea, weight loss, insomnia) and a 34.2 percent treatment discontinuation rate. Reldesemtiv does not activate slow skeletal or cardiac troponin complexes, providing a selectivity basis for its intended use in conditions characterized by fast skeletal muscle weakness secondary to attenuated neuronal input, including amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and chronic obstructive pulmonary disease. In a Phase 1 pharmacodynamic study in 16 healthy volunteers, reldesemtiv amplified the tibialis anterior force-frequency response by approximately 60 percent at 10 Hz nerve stimulation at the highest plasma concentrations tested, confirming the mechanism of action in human skeletal muscle. Pharmacokinetics across five Phase 1 studies demonstrated dose-proportional exposure with a terminal half-life of approximately 5 to 14 hours depending on dose, a time to peak concentration of 2 to 3 hours, and similar pharmacokinetic profiles in young and elderly subjects. The Phase 2 FORTITUDE-ALS trial (n=458; 12 weeks; placebo, 150, 300, or 450 mg twice daily) did not reach statistical significance on its primary endpoint of slow vital capacity change (p=0.11), though trends favoring reldesemtiv were observed across all three endpoints and a post hoc analysis of the ALSFRS-R functional scale reached nominal significance (p=0.01). The Phase 2 SMA study (n=70; 8 weeks; 150 or 450 mg twice daily) reported statistically significant improvement in six-minute walk distance at week 4 (35.6 m, p=0.0037) and maximum expiratory pressure at week 8 (13.2 cmH2O, p=0.03) in the 450 mg group, with concentration-response relationships in the highest plasma concentration quartile reaching significance on both endpoints. The Phase 3 COURAGE-ALS trial (n=486; 24 weeks; 300 mg twice daily versus placebo; 83 centers in 16 countries) was terminated for futility at the second planned interim analysis when conditional power for the primary endpoint (ALSFRS-R score change at 24 weeks) was 8.4 percent. The primary analysis showed a mean difference of negative 1.1 points (95 percent CI, negative 2.17 to negative 0.08; p=0.04), numerically favoring placebo. No preplanned subgroup favored reldesemtiv. The compound is not approved by any regulatory authority for any indication. This monograph reviews the chemistry, discovery, molecular pharmacology, pharmacokinetics, preclinical and clinical evidence, sourcing, handling, adverse events, and a comparative assessment of reldesemtiv against tirasemtiv, tofersen, riluzole, edaravone, and risdiplam on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1658Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 22, 2026
Roluperidone

Our opinion on this compoundNovel, promising

65/100

Novel sigma-2/5-HT2A profile targets schizophrenia negative symptoms without dopamine; FDA CRL tempers but doesn’t erase the signal

Look, the negative symptom problem in schizophrenia has been essentially unsolved for fifty years. Dopamine blockade handles positive symptoms reasonably well; it does almost nothing durable for avolition, alogia, and social withdrawal. Roluperidone is interesting precisely because it doesnt touch dopamine at all. No D1 through D5 binding, essentially. That alone makes it worth paying attention to.

The receptor story here is genuinely novel. The sigma-2 receptor sat in pharmacology textbooks as an orphan target for decades, and its molecular identity wasn’t confirmed until 2017, when Chu et al. established it as TMEM97, a transmembrane protein involved in calcium signaling, cholesterol homeostasis, and autophagy regulation. Roluperidone hits TMEM97 at Ki 8.19 nM, equipotent with its 5-HT2A affinity (Ki 7.53 nM). The 5-HT2A component also matters: chronic antagonism normalizes slow-wave sleep architecture, a deficit that tracks closely with negative symptom burden in schizophrenia. The mechanism isn’t just novel; theres a real biological rationale underneath it, and downstream effects on glutamatergic and dopaminergic tone via sigma-2 modulation add another layer worth investigating.

The clinical story is more complicated. Phase 2b (MIN-101C03, 244 patients) was genuinely clean: 32 mg and 64 mg doses both hit statistical significance on the PANSS negative subscale at 12 weeks, with effect sizes of 0.45 and 0.58. Those are respectable numbers for a notoriously hard-to-move symptom cluster. Phase 3 (EMERGENT-3, 513 patients) was murkier. The 64 mg arm hit nominal significance (p = 0.044, effect size 0.26) on the primary endpoint, plus a statistically significant improvement on the PSP social functioning scale. But the FDA issued a complete response letter in February 2024, citing insufficient evidence from a single adequate trial. Regulatory reality: Minerva got one positive phase 3, FDA wanted two. That’s a real setback, though it isn’t the same as a failed trial. The network intervention analysis identifying avolition as the directly targeted symptom is actually one of the more methodologically interesting findings in recent negative symptom research.

What we think is genuinely valuable here is the bench utility. If you’re studying sigma-2/TMEM97 biology in cortical or hippocampal neurons, roluperidone is currently the most clinically characterized selective antagonist available. The preclinical data on downstream neuroplasticity and neurotrophic effects are undercharacterized, and thats exactly what makes this a productive target for investigation. The compound lets you ask sigma-2 questions you simply can’t ask with anything else that has a human pharmacokinetic profile attached to it.

The main limitations are the modest phase 3 effect size, the FDA’s unresolved status, and incompletely mapped sigma-2 downstream biology. CYP2D6 metabolizer status adds a translational wrinkle. We wouldn’t call this a solved story. But the receptor angle is novel enough, and the clinical signal is real enough, that investigators in negative symptom neurobiology or nondopaminergic neuropsychiatric pharmacology should have roluperidone on their radar.

Novelty

65

Mechanism promise

72

In-category differentiation

70

Evidence quality

55

Translational signal

60

Research bench value

68

Rationale Roluperidone scores well on novelty and mechanism for its dopamine-free sigma-2/TMEM97 pharmacology in a historically undrugged indication, but modest phase 3 effect sizes and the FDA’s complete response letter limit evidence and translational scores; genuine bench utility as the most clinically characterized sigma-2 antagonist keeps it firmly in novel-promising territory.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Sigma-2 receptor antagonist and serotonin 5-HT2A receptor antagonist with alpha-1A adrenergic receptor antagonism

A cyclic amide derivative with equipotent nanomolar antagonism at sigma-2 and 5-HT2A receptors, developed by Minerva Neurosciences as monotherapy for the negative symptoms of schizophrenia and distinguished from conventional antipsychotics by the absence of dopaminergic receptor binding.

Abstract

Roluperidone (MIN-101, formerly MT-210 and CYR-101) is a cyclic amide (isoindolinone) derivative that combines high-affinity antagonism at the sigma-2 receptor (TMEM97; Ki 8.19 nM) and the serotonin 5-HT2A receptor (Ki 7.53 nM) with lower-affinity antagonism at alpha-1A adrenergic receptors (Ki 4.17 nM), while exhibiting essentially no binding at dopamine D1 through D5 receptors, muscarinic, cholinergic, or histaminergic receptors. This receptor binding profile distinguishes roluperidone from all marketed antipsychotics and underwrites a pharmacological rationale for addressing the negative symptoms of schizophrenia through nondopaminergic mechanisms. The sigma-2 receptor, identified in 2017 as the transmembrane protein TMEM97, is expressed at high density in cortical and hippocampal neurons and is implicated in calcium signaling, cholesterol homeostasis, autophagy, and the modulation of dopaminergic and glutamatergic neurotransmission. The 5-HT2A antagonist component promotes slow-wave sleep normalization, a deficit that is consistently documented in schizophrenia and that correlates with negative symptom severity. Roluperidone was originally synthesized by Mitsubishi Tanabe Pharma Corporation (designated MT-210), licensed through Cyrenaic Pharmaceuticals (CYR-101), and advanced through clinical development by Minerva Neurosciences (MIN-101). In a Phase 2b randomized, double-blind, placebo-controlled trial of 244 patients with stable schizophrenia and moderate-to-severe negative symptoms (MIN-101C03), roluperidone monotherapy at 32 mg/day and 64 mg/day produced statistically significant improvement on the PANSS negative symptom factor score at 12 weeks (effect sizes 0.45 and 0.58, respectively; both p < 0.025). In the subsequent Phase 3 trial (EMERGENT-3, NCT03397134, 513 patients), the 64 mg/day dose reached nominal statistical significance on the primary negative symptom endpoint in the modified intent-to-treat analysis (p = 0.044, effect size 0.26), with statistically significant improvements in social functioning on the Personal and Social Performance scale (p = 0.021, effect size 0.27) and a negative symptom responder rate of 39% versus 23% on placebo (p = 0.006). Network intervention analysis of both trials identified avolition as the directly targeted symptom, with improvements cascading across the broader negative symptom constellation. Pharmacokinetics are characterized by oral bioavailability of 73% to 81%, peak plasma concentration at approximately 3.5 hours, and a plasma elimination half-life of approximately 7 hours after a 64 mg dose, supporting once-daily administration. CYP2D6 is involved in metabolism, and poor or intermediate CYP2D6 metabolizers were excluded from the Phase 3 trial. Tolerability across both trials was notable for the absence of clinically meaningful weight gain, metabolic changes, extrapyramidal symptoms, or prolactin elevation; the principal safety signal was QTc interval prolongation leading to discontinuation of three patients at the 64 mg dose in the Phase 3 trial. Minerva Neurosciences filed a New Drug Application with the U.S. Food and Drug Administration in April 2023. The FDA issued a Complete Response Letter in February 2024, citing insufficient evidence of effectiveness from a single adequate trial, absence of data on concomitant antipsychotic administration, and the need for additional evidence of clinical meaningfulness. The compound remains in development as of the monograph date. This monograph documents the chemistry, dual-receptor pharmacology, pharmacokinetics, preclinical and clinical evidence base, safety profile, and a comparative assessment of five compounds in the negative symptom treatment space against roluperidone on five competency standards. The compound is investigational and is not approved by any regulatory authority for any indication.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1657Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 22, 2026
Aficamten

Our opinion on this compoundEstablished, active research

70/100

Second-gen cardiac myosin inhibitor with FDA approval, a distinct allosteric site, and genuinely rigorous phase 3 evidence in HCM

Look, the cardiac myosin inhibitor class is one of the genuinely new things that happened in cardiovascular pharmacology in the last decade. The idea of intervening directly at the sarcomere rather than working upstream through adrenergic receptors or calcium channels represents a real conceptual break from fifty years of HCM management. Aficamten sits in that class as the second approved agent, but its binding site is not just a pharmacokinetic tweak on mavacamten: it overlaps with the blebbistatin pocket rather than mavacamten’s canonical site, and it slows phosphate release from the myosin ATPase cycle to rates slower than the conventional super-relaxed state. Thats a meaningful mechanistic distinction, not a minor structural refinement.

What we like here is the evidence architecture. The SEQUOIA-HCM pivotal trial is a proper Phase 3 RCT with hard hemodynamic and functional endpoints, and MAPLE-HCM adds the direct head-to-head comparison with metoprolol that the field had been asking for since mavacamten approval. ACACIA-HCM extends the question into non-obstructive disease, and FOREST-HCM provides the long-term extension read. For a compound still under two years old as an approved drug, that is a dense and methodologically disciplined program. FDA sign-off in December 2025 reflects a trial package that survived real regulatory scrutiny.

The differentiation story is genuine but not yet decisive. Aficamten’s engineered PK profile reduces the CYP2D6 variability that makes mavacamten titration complicated in real-world polypharmacy patients. The faster off-kinetics are clinically relevant for a drug that requires LVEF monitoring and rapid dose adjustment. But we’re honest that two allosteric cardiac myosin inhibitors competing for the same indication with overlapping mechanisms leaves the superiority question open. FOREST-HCM will help close it. Right now, aficamten is clearly best-in-class on pharmacokinetic manageability; it’s not yet clearly best-in-class on outcomes.

For bench investigators, the blebbistatin-pocket binding gives aficamten probe value that mavacamten does not replicate exactly. If you’re studying pre-power-stroke state stabilization or trying to dissect myosin ATPase kinetics in disease models, having two chemically distinct agents at different allosteric sites is genuinely useful. The feline spontaneous HCM model work also provides a translational bridge that transgenic-only programs don’t, which matters for groups working in naturally occurring disease.

Honestly, what keeps the score at 70 rather than climbing into the 80s is scale and novelty ceiling. HCM affects roughly 1 in 500 people, which is not the metabolic field where the GLP-1 agents are reshaping population-level outcomes. The mechanism, while elegant, is now second-in-class in its own category. And the evidence base, strong as it is, comes from a single-developer program in a single indication. Aficamten is a serious compound with serious data, best-in-class on several dimensions. It is not a field-reshaping discovery; it’s the second, better-engineered answer to a real clinical problem.

Novelty

60

Mechanism promise

78

In-category differentiation

65

Evidence quality

80

Translational signal

78

Research bench value

60

Rationale Aficamten earns strong mechanism and evidence scores as the only second approved sarcomere-level agent in HCM, with a binding site distinct from mavacamten and multiple Phase 3 programs culminating in December 2025 FDA approval; novelty is tempered by being second-in-class in a narrow indication and differentiation from mavacamten remains partially unresolved in long-term extension data.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective small-molecule allosteric inhibitor of cardiac beta-myosin heavy chain (MYH7) ATPase activity

A next-generation cardiac myosin inhibitor developed by Cytokinetics as CK-3773274, engineered for optimized pharmacokinetic properties relative to mavacamten, approved by the United States Food and Drug Administration in December 2025 for the treatment of symptomatic obstructive hypertrophic cardiomyopathy under the trade name MYQORZO.

Abstract

Aficamten (CK-3773274, trade name MYQORZO) is a selective, allosteric, reversible small-molecule inhibitor of cardiac myosin motor activity developed by Cytokinetics, Inc. for the treatment of hypertrophic cardiomyopathy (HCM). The compound reduces myocardial contractility by stabilizing a weak actin-binding, pre-power-stroke state of the beta-cardiac myosin head, thereby decreasing the number of functional myosin cross-bridges available during each cardiac cycle and attenuating the left ventricular outflow tract (LVOT) obstruction that drives symptoms in obstructive HCM. Aficamten binds to an allosteric site between the upper 50 kDa and lower 50 kDa subdomains of the myosin catalytic domain, overlapping with the blebbistatin binding pocket but distinct from the mavacamten binding site, and dramatically slows phosphate release from the myosin ATPase cycle to a rate slower than the conventional super-relaxed state.

The compound was engineered to address pharmacokinetic limitations of mavacamten, the first-in-class cardiac myosin inhibitor. Aficamten achieves a plasma elimination half-life of approximately 75 to 100 hours (compared to 7 to 9 days for mavacamten), reaches steady-state plasma concentrations within approximately 2 weeks of daily dosing (compared to approximately 6 weeks for mavacamten), demonstrates reversibility of pharmacodynamic effects within 24 to 48 hours, exhibits a shallow exposure-response relationship that widens the therapeutic window, and is metabolized by multiple cytochrome P450 enzymes (CYP2C9, CYP3A4, CYP2D6, CYP2C19) rather than predominantly by the polymorphic CYP2C19, thereby reducing the drug-drug interaction burden and eliminating the requirement for CYP metabolizer genotyping.

Clinical development of aficamten has proceeded through a comprehensive program. The Phase 1 dose-escalation study in 102 healthy participants demonstrated dose-proportional pharmacokinetics, dose-dependent reductions in left ventricular ejection fraction (LVEF), and favorable tolerability with no serious adverse events. The Phase 2 REDWOOD-HCM trial in patients with symptomatic obstructive HCM demonstrated statistically significant reductions in resting and post-Valsalva LVOT gradients, with 78.6 to 92.9 percent of patients achieving target gradient reduction at 10 weeks. The pivotal Phase 3 SEQUOIA-HCM trial randomized 282 patients with symptomatic obstructive HCM to aficamten or placebo for 24 weeks and met its primary endpoint of improved peak oxygen uptake (pVO2), with a least-squares mean difference of 1.74 mL/kg/min (p = 0.000002), along with statistically significant improvements in all 10 prespecified secondary endpoints including NYHA functional class, Kansas City Cardiomyopathy Questionnaire scores, and LVOT gradient reduction. The Phase 3 MAPLE-HCM trial demonstrated superiority of aficamten monotherapy over metoprolol monotherapy, with a pVO2 least-squares mean difference of 2.3 mL/kg/min (p < 0.0001). The Phase 3 ACACIA-HCM trial in 516 patients with non-obstructive HCM met both dual primary endpoints for symptom burden and exercise capacity improvement.

The United States Food and Drug Administration approved aficamten on December 19, 2025, for the treatment of adults with symptomatic obstructive HCM to improve functional capacity and symptoms, marketed as MYQORZO. The approval includes a boxed warning regarding the risk of heart failure due to systolic dysfunction and a Risk Evaluation and Mitigation Strategy (REMS) requiring echocardiographic monitoring. The principal adverse reaction observed at greater than 5 percent incidence above placebo was hypertension (8 percent versus 2 percent). LVEF reduction below 50 percent occurred in 3.5 percent of aficamten-treated patients in SEQUOIA-HCM compared to 0.7 percent on placebo; all instances were mild, reversible, and not associated with clinical heart failure events. This monograph reviews the chemistry, mechanism, pharmacokinetics, preclinical and clinical evidence, safety profile, handling considerations, and comparative assessment of aficamten against five alternative agents for the management of hypertrophic cardiomyopathy.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1622Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 21, 2026

←Previous Page

1 2 3 4 5 6 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.